Evaluation of Renal Impairment Impact on Aticaprant (JNJ-67953964) Pharmacokinetics in Healthy Adults: An Open-label, Single-dose Study

The primary objective of this study is to evaluate the effect of **renal impairment** on the pharmacokinetics of **Aticaprant** (JNJ-67953964) in healthy adult participants. Understanding the pharmacokinetic profile in individuals with varying degrees of renal function is clinically relevant as it informs dosing adjustments and safety considerations for patients with renal impairment. This study aims to provide critical data that can guide healthcare professionals in optimizing therapeutic strategies for patients with compromised renal function.

The clinical trial involves **healthy adult participants** with an age range corresponding to categories 3 and 4, which typically include individuals aged 18 to 64 years. The study population comprises both male and female subjects, indicating a gender-inclusive approach. The trial does not specifically exclude vulnerable populations, suggesting a broad participant base. However, the sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population are not detailed, and there is no specific mention of lifestyle considerations such as diet, physical activity, or habits. The absence of detailed inclusion or exclusion criteria implies a focus on a general healthy adult demographic without specific health conditions. The sponsor has not disclosed the main objective of the trial.

The clinical trial is designed as an **open-label**, single-dose study to evaluate the effect of renal impairment on the pharmacokinetics of Aticaprant (JNJ-67953964) in **healthy adult participants**. The trial is categorized under Phase 3, indicating it is in the later stages of clinical research, focusing on the efficacy and monitoring of adverse reactions. The trial is expected to commence recruitment on January 2, 2024, and conclude by July 26, 2024, marking the overall trial duration.

Participants will undergo a sequence of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following the initial screening, participants will receive a single dose of the investigational product. Subsequent follow-up visits will be scheduled to monitor the pharmacokinetic parameters and assess any potential adverse effects. The end-of-study visit will conclude the participant's involvement, ensuring all necessary data is collected and any remaining health assessments are completed.

The expected length of participant involvement will span from the initial screening through to the end-of-study visit, aligning with the trial's overall timeline. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The study's design and procedures are structured to ensure the collection of reliable data while maintaining participant safety and adherence to ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 2, 2024, with an estimated completion date of July 26, 2024. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent with clinical standards. The trial's primary focus is to evaluate the treatment's effectiveness within the specified timeframe, adhering to the rigorous standards expected in a Phase 3 clinical trial.